Q3 2023
Released Nov 3, 2023, after the close
10-Q filed Nov 3, 2023, 34 days after period end · 0001628280-23-036777
Q3 2023 · 10-Q
Revenue$0.00$0.00 no prior Q3 2022 on fileno prior Q2 2023 on file
Net Income-$50.71M-$50.71M N/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$0.55-$0.55 N/M vs Q3 2022N/M vs Q2 2023
Operating Income-$51,459,000N/M
Operating Cash Flowderived-$39,166,000N/M
Free Cash Flowderived-$42,075,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|
| Revenue | $0.00 | — | — |
| Net Income | -$50.71M | -$29.35M | -$16.41M |
| EPS Diluted | -$0.55 | -$1.61 | -$1.52 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR